Exploring Oncology Clinical Design
Webinar date & time: March 9th 14:00 CET
Join us for an engaging and educational webinar on the topic of “Exploring Oncology Clinical Design”. This webinar will provide you with valuable insights and the latest information on oncology clinical design.
You’ll have the opportunity to hear from expert speakers who will share their experience and knowledge on the subject. Whether you’re a healthcare professional, researcher, or simply interested in the field of oncology, this webinar is a must-attend event. Register now to secure your spot!
The webinar will lead by our field experts, who share their experiences and best practices. So let’s dive in and explore the complexities and opportunities of Oncology Clinical Trial Design.
During the webinar we’ll discuss:
- Dose escalation designs
- Early phase study – endpoints
- Protocol – schedule of assessment considerations
Register here!
Regina Auskalnienė - MD
Chief Global Clinical Research Officer
Regina Auskalniene is a Medical Doctor, cardiologist. She has over 13 years of experience in Clinical Research and has been leading our Clinical Operations department since April 2018, overseeing Clinical Monitoring, Project Management and Start-up activities in the region.
Read more.
Vladimir Mukovozchik, MD
Head of Project Management
Vladimir has over 16 years of experience in clinical research. He has been working in global CROs on managerial roles for many years and has been leading our project management department since 2022. He has extensive experience in different therapeutic areas with the main expertise lying in the oncology field.
Planning Your Next Oncology Trial?
Let’s talk how we can help you design oncology trials that get you the results you need to improve patient lives.
Other content that might interest you:
What is a Safety Signal?
Occasionally we see the information of a safety signal for medical product, but what does it really mean? We can describe the safety signal as an indication for new and significant safety-related data for a marketed product. The new data could indicate a new potentially causal association between an adverse event, beneficial response and a medical product, or a new aspect of causal association that was previously known. Usually, a signal will be relevant for all products with the same active ingredient, including the combination products. Further, let’s look more at the main steps of the safety signal management.
Local Literature Surveillance Challenges and Specifics in the EU, CIS and LATAM regions
PV legislation introduced by the European Commission in 2012 and GVP guidelines together with local requirements committed each MAH to perform literature review in countries where their products are present. Compliance with mandatory requirements and guidelines is not always a simple task when local requirements and specifics come along. In this article, we will take a closer look at these challenges and specifics for local literature surveillance in different regions as EU, CIS and LATAM.
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)
On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.
